Abstract: Disclosed herein are polynucleotides encoding multi-epitope polypeptides and assemblies thereof, and their use for treating or limiting Toxoplasma gondii infection.

Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.

Abstract: This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp.

Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.

Abstract: Provide is a novel prophylactic and/or therapeutic agent for Streptococcus pneumoniae infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and/or treat Streptococcus pneumoniae infection. The prophylactic and/or therapeutic agent for Streptococcus pneumoniae infection, comprises a bacterium belonging to the genus Enterococcus. Also provided are: a medicine for prevention and/or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus; and a food for prevention and/or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus.

Abstract: Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp.) antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including formulations that effectively preserve microbial cell viability during freeze-thaw or freeze-drying. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.

Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.

Abstract: Single-domain antibodies (SAbs) against three Yersinia pestis surface proteins (LcrV, YscF, and F1), nucleic acid sequences encoding the SAbs, and polypeptides comprising two or more SAbs capable of recognizing two or more epitopes and/or antigens. The present invention further includes methods for preventing or treating Y. pestis infections in a patient; methods for detecting and/or diagnosing Y. pestis infections; and devices and methods for identifying and/or detecting Y. pestis on a surface and/or in an environment.

Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Abstract: The invention provides compositions comprising flagellin polypeptides from bacterial strains and the use of such compositions in the treatment of disease.

Abstract: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.

Abstract: The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

Abstract: The present disclosure relates to a novel strain for inhibiting a Chinese cabbage soft rot disease from microorganisms isolated from samples of a bacillus source of soil polluted with a soft-rot disease, a culture medium and crude extract using the culture medium, an environmentally friendly plant disease control agent using same, and a method for utilizing same as an environment-friendly preparation biopesticide by using same as a raw material. The present disclosure also relates to a control method for treating soils or plants using an environmentally friendly Chinese cabbage soft-rot disease control agent through various formulation methods by using the strain, a culture medium thereof, and a crude extract thereof.

Abstract: The present invention relates to pharmaceutical preparations for the treatment or the prevention of a Staphylococcal infection. They contain at least one polypeptide epitope, wherein said at least one polypeptide epitope induces protective antibodies in a patient in need thereof. The polypeptide epitopes according to the present invention can preferably be used for the preparation of a vaccine against a Staphylococcal infection, such as Staphylococcus aureus, including Staphylococcus aureus (MRSA). The present invention further relates to monoclonal antibodies capable of recognizing and binding to a polypeptide epitope according to the present invention, and the invention also relates to the use of the monoclonal antibodies for diagnosis and the prevention or therapy of Staphylococcal infection, including MRSA.

Abstract: The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other recombinant protein expression systems delivered as a vaccine formulation.